SELLAS Life Sciences Group, Inc. (SLS)
Stock Price:
$3.49 USD
-0.07 (-1.97%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $3.54 +0.05 (1.43%) Aug 3, 7:59 PM
Key Info
| Market Cap |
23.45M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-18.90M |
| Shares Out |
6.72M |
| EPS (ttm) |
-6.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$3.49 |
| Previous Close |
$3.56 |
| Change ($) |
-0.07 |
| Change (%) |
-1.97% |
| Day's Open |
3.55 |
| Day's Range |
3.40 - 3.68 |
| Day's Volume |
2,994,655 |
| 52-Week Range |
1.46 - 10.89 |
More Stats
| Market Cap |
23.45M |
| Enterprise Value |
16.72M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.72M |
| Float |
6.29M |
| EPS (basic) |
-9.39 |
| EPS (diluted) |
-6.73 |
| FCF / Share |
-3.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
166,460 |
| Short Ratio |
1.36 |
| Short % of Float |
3.09% |
| Beta |
1.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.67 |
| Revenue |
n/a |
| Operating Income |
-19.75M |
| Net Income |
-18.90M |
| Free Cash Flow |
-19.48M |
| Net Cash |
6.72M |
| Net Cash / Share |
1.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-66.16% |
| ROE |
-343.23% |
| ROIC |
-441.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
9.00
Current: $3.49
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -20.04 | -31.09 | -23.04 | -16.51 | -34.22 | -43.90 | -28.49 | -21.20 | -12.49 | -16.63 |
| Net Income | -19.29 | -27.67 | -23.75 | -17.68 | -63.90 | -36.61 | -76.68 | -34.97 | -11.49 | -11.99 |
| Shares Outstanding | 2.56 | 0.26 | 0.05 | 0.02 | 0.01 | - | - | - | - | - |
| Earnings Per Share | -10.92 | -157.72 | -522.00 | -933.00 | -12,346.24 | -9,195.92 | -25,502.55 | -16,801.68 | -9,600.96 | -20,102.01 |
| Operating Cash Flow | -17.64 | -30.42 | -10.99 | -11.85 | -48.16 | -42.87 | -28.93 | -20.97 | -14.67 | -10.26 |
| Capital Expenditures | - | - | - | - | -0.15 | -0.06 | -0.32 | - | -0.05 | -0.11 |
| Free Cash Flow | -17.64 | -30.42 | -10.99 | -11.85 | -48.31 | -42.93 | -29.25 | -20.97 | -14.72 | -10.36 |
| Cash & Equivalents | 7.38 | 5.45 | 12.75 | 6.05 | 30.13 | 23.85 | 47.99 | 35.59 | 11.54 | 6.91 |
| Total Debt | 0.22 | - | 10.99 | 7.37 | 4.74 | 8.40 | 9.89 | 0.06 | 0.57 | 0.07 |
| Net Cash / Debt | 7.16 | 5.45 | 1.76 | -1.32 | 25.39 | 15.45 | 38.10 | 35.53 | 10.97 | 6.84 |
| Assets | 16.61 | 16.92 | 33.53 | 6.42 | 82.14 | 80.49 | 87.98 | 54.99 | 30.97 | 7.48 |
| Liabilities | 10.52 | 11.67 | 31.46 | 11.42 | 68.63 | 43.43 | 82.09 | 27.23 | 20.86 | 5.05 |
| Book Value | 6.09 | 5.25 | 2.07 | -5.00 | 13.51 | 37.06 | 5.89 | 27.76 | 10.11 | 2.43 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
SELLAS Life Sciences Group, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Angelos M. Stergiou |
Stock Information
| Ticker Symbol |
SLS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SLS |
Description
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.